PBAC's latest decision on Teduglutide: Recommended with restriction (2021). Considered for Type III (chronic) short bowel syndrome with intestinal failure in paediatric patients aged 2 years and above who are dependent on parenteral support.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
4
first 2017
Submissions
4
2017 → 2021
Eligible population
Paediatric patients (aged 2 years and above) with Type III chronic short bowel syndrome with intestinal failure who are dependent on parenteral support and have been on a stable parenteral support regimen for at least 3 days per week in the previous 4 weeks.
Therapy area
Gastroenterology
Line of therapy
Any
Evidence base
RCT
Primary endpoint
Parenteral support reduction
Key trials
Carter et al. (2017), Hill et al. (2018)
Economic model
Not modelled
ICER note
This is a minor submission requesting amendments to existing Authority Required listing; no new economic evaluation was undertaken.
Submission history
Nov 2017: Noted · Authority Required
Jul 2018: Not recommended · Authority Required
Mar 2019: Recommended with restriction · Authority Required
Mar 2021: Recommended with restriction · Authority Required